NASDAQ:GMAB
Genmab A/S Stock News
$25.15
+0.250 (+1.00%)
At Close: Jul 03, 2024
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
02:00am, Friday, 28'th Jun 2024
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive
Completion of Share Buy-back Program
05:00pm, Thursday, 27'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announc
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
07:08pm, Wednesday, 26'th Jun 2024
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults w
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
07:03pm, Wednesday, 26'th Jun 2024
Company Announcement Approval based on results from Phase 1/2 EPCORE ® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL
7 Biotech Stocks to Buy on the Dip: June 2024
12:56pm, Monday, 24'th Jun 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
Transactions in Connection with Share Buy-back Program
09:55am, Monday, 24'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billio
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:45pm, Tuesday, 18'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The increas
Transactions in Connection with Share Buy-back Program
09:33am, Monday, 17'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billio
Grant of Restricted Stock Units and Warrants to Employees in Genmab
03:45pm, Wednesday, 12'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02:50pm, Tuesday, 11'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, t
Transactions in Connection with Share Buy-back Program
10:18am, Monday, 10'th Jun 2024
Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billio
7 Stocks That Could Safely 10X by 2030
06:19am, Thursday, 06'th Jun 2024
There is no such thing as safe gains in the market, at least in the near term. However, many stocks are very solid and won't disappoint you in the long run.
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
12:51pm, Wednesday, 05'th Jun 2024
Media Release COPENHAGEN, Denmark; June 05, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate
Transactions in Connection with Share Buy-back Program
09:09am, Monday, 03'rd Jun 2024
Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that data from the Phase 2 innovaTV 207 trial (NCT03485209) Part C (n=40), investigating tisotumab vedotin, an antibody-